Daniel Small, PhD
Dan focuses on Oncology Preclinical Discover Services. He holds a PhD in Biology from the University of Ottawa. He began his career in the field of neuroscience and spent seven years at the National Research Council of Canada studying stroke and neurodegeneration and then ive years at Lexicon Pharmaceuticals phenotyping 3500 transgenic mouse knock out lines. He also worked with CROs, MDS Pharma Services, Ricerca Biosciences and Numira Biosciences, where he provided scientific support to clients in the area of fibrosis, inflammation and oncology. In the last 22 years he has generated over 70 publications in the area of drug development.